Table 3.
Summary of patient baseline characteristics dichotomized by Gleason score into a less aggressive “≤3 + 4” cohort and more aggressive “≥4 + 3” cohort.
| Characteristics | ≤3 + 4 (n = 32) | ≥4 + 3 (n = 28) | p |
|---|---|---|---|
| Age, years | 58 ± 8 | 65 ± 7 | 0.006 |
| PSA, µg/L | 6.04 ± 5.21 (30) | 7.79 ± 5.65 (28) | 0.01 |
| BMI, kg/m2 | 26.8 ± 3.5 (32) | 27.0 ± 3.3 (25) | 0.70 |
| Waist Circumference, cm | 93.7 ± 8.9 (26) | 98.1 ± 8.1 (24) | 0.054 |
| Pathological T Stage | |||
| T2 | 19 | 10 | |
| T3a | 13 | 14 | |
| T3b | 1 | 3 | |
| T4 | 0 | 0 | |
| Blood Serum | |||
| Glucose, mmol/L | 5.2 ± 0.6 | 5.4 ± 0.8 | 0.34 |
| Insulin, pmol/L | 29 ± 19 | 33 ± 26 | 0.72 |
| Cholesterol, mmol/L | 4.6 ± 1.0 | 4.5 ± 0.9 | 0.61 |
| Triacylglycerols, mmol/L | 1.3 ± 0.5 | 1.2 ± 0.3 | 0.82 |
| HDL, mmol/L | 1.3 ± 0.4 | 1.3 ± 0.4 | 0.56 |
| LDL, mmol/L | 2.6 ± 1.0 | 2.6 ± 0.8 | 0.81 |
Mean ± SD (n) except for the pathological T stage, which is the number of cases.